Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

Nature Cell Biology

Volumn 10, Issue 12, 2008, Pages 1470-1476

  Skog, Johan ^a   Würdinger, Tom ^a,b   van Rijn, Sjoerd ^a   Meijer, Dimphna H ^a   Gainche, Laura ^a   Curry, William T ^a   Carter, Bob S ^a   Krichevsky, Anna M ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MICRORNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTANT; PRIORITY JOURNAL; PROTEIN TRANSPORT; RNA TRANSPORT; TUMOR GROWTH; TUMOR PROMOTION;

ANGIOGENESIS INDUCING AGENTS; CELL PROLIFERATION; ENDOTHELIAL CELLS; EXOSOMES; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RNA; RNA TRANSPORT; TUMOR MARKERS, BIOLOGICAL;

EID: 57049103401     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1800     Document Type: Article

References (37)

1. Stupp, R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987-996 (2005).
2. Mazzocca, A., et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65, 4728-4738 (2005).
3. Muerkoster, S., et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res. 64, 1331-1337 (2004).
4. Singer, C. F., et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res. Treat. 110, 273-281 (2008).
5. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
6. Gabrilovich, D. I. Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr. Cancer Drug Targets 7, 1 (2007).
7. Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A. & Ratajczak, M. Z. Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487-1495 (2006).
8. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: Composition, biogenesis and function. Nature Rev. Immunol. 2, 569-579 (2002).
9. Pan, B. T. & Johnstone, R. M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. Cell 33, 967-978 (1983).
10. Booth, A. M., et al. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J. Cell Biol. 172, 923-935 (2006).
11. Greco, V., Hannus, M. & Eaton, S. Argosomes: A potential vehicle for the spread of morphogens through epithelia. Cell 106, 633-645 (2001).
12. Delves, G. H., Stewart, A. B., Cooper, A. J. & Lwaleed, B. A. Prostasomes, angiogenesis, and tissue factor. Semin. Thromb. Hemost. 33, 75-79 (2007).
13. Mack, M., et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nature Med. 6, 769-775 (2000).
14. Al-Nedawi, K., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biol. 10, 619-624 (2008).
15. Valadi, H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol. 9, 654-659 (2007).
16. Baj-Krzyworzeka, M., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol. Immunother. 55, 808-818 (2006).
17. Chaput, N., Taieb, J., Andre, F. & Zitvogel, L. The potential of exosomes in immunotherapy. Exp. Opin. Biol. Ther. 5, 737-747 (2005).
18. Wieckowski, E. & Whiteside, T. L. Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol. Res. 36, 247-254 (2006).
19. Clayton, A., Mitchell, J. P., Court, J., Mason, M. D. & Tabi, Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 67, 7458-7466 (2007).
20. Ginestra, A., et al. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res. 18, 3433-3437 (1998).
21. Liu, C., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375-1385 (2006).
22. Janowska-Wieczorek, A., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752-760 (2005).
23. Millimaggi, D., et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9, 349-357 (2007).
24. Tannous, B. A., Kim, D. E., Fernandez, J. L., Weissleder, R. & Breakefield, X. O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11, 435-443 (2005).
25. Pelloski, C. E., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol. 25, 2288-2294 (2007).
26. Nishikawa, R., et al. Immunohistochemical analysis of the mutant epidermal growth factor, δEGFR, in glioblastoma. Brain Tumor Pathol. 21, 53-56 (2004).
27. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029-6033 (2005).
28. Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncology 7, 122-133 (2005).
29. Eberle, K., et al. The expression of angiogenin in tissue samples of different brain tumours and cultured glioma cells. Anticancer Res. 20, 1679-1684 (2000).
30. Rolhion, C., et al. Interleukin-6 overexpression as a marker of malignancy in human gliomas. J. Neurosurg. 94, 97-101 (2001).
31. Taraboletti, G., et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 8, 96-103 (2006).
32. Xu, Z. P., Tsuji, T., Riordan, J. F. & Hu, G. F. Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression. Biochemistry 42, 121-128 (2003).
33. Kislauskis, E. H., Zhu, X. & Singer, R. H. Sequences responsible for intracellular localization of β-actin messenger RNA also affect cell phenotype. J. Cell Biol. 127, 441-451 (1994).
34. Mallardo, M., et al. Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain. Proc. Natl Acad. Sci. USA 100, 2100-2105 (2003).
35. Sonabend, A. M., Dana, K. & Lesniak, M. S. Targeting epidermal growth factor receptor variant III: A novel strategy for the therapy of malignant glioma. Exp. Rev. Anticancer Ther. 7, S45-S50 (2007).
36. Mellinghoff, I. K., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Engl. J. Med. 353, 2012-2024 (2005).
37. Badr, C. E., Hewett, J. W., Breakefield, X. O. & Tannous, B. A. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2, e571 (2007).